Hepatoprotection of Jianpi Qingre Lishi prescription on non-alcoholic steatohepatitis miRNA-27/peroxisome proliferator-activated receptor gamma axis.

Authors

X U Mengjun, Yan Zixing, Chen Xi, Cai Juanjuan, Zhang Haiou, Lin Zhenwen

Published in

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. Volume 46. Issue 3. Pages 561-570.

Abstract

To elucidate the molecular targets and physiological mechanisms underlying the therapeutic efficacy of Jianpi Qingre Lishi prescription (, JQLP) in the treatment of non-alcoholic steatohepatitis (NASH).
This study used 120 Sprague-Dawley rats to establish six groups at random (n = 20): blank control (BC), model, low-dose JQLP (L-JQLP), medium-dose JQLP (M-JQLP), high-dose JQLP (H-JQLP), and positive control (PC) groups. Rats in the BC group received a diet with methionine- and choline-sufficient (MCS), while those in the remaining groups were fed with methionine- and choline-deficient (MCD) diet. Blood samples were collected for biochemical analyses and inflammatory factors determination; while liver tissues were harvested to identify the histological alterations through hematoxylin-eosin staining and oil red O staining. In addition, the levels of miRNA-27 (miR-27) and peroxisome proliferator-activated receptor γ (PPARγ) were determined utilizing quantitative real-time polymerase chain reaction and Western blotting.
Compared to the BC group, the model group showed no significant changes in fasting blood glucose (FBG), which was substantially reduced after both M-JQLP and H-JQLP treatments. MCD diet induced a series of pathological alterations, such as extensive vacuole-like steatosis, disorganized hepatic plates, and significant inflammatory cell infiltration in liver tissues, which were dose-dependently weakened by JQLP intervention. Rats fed with MCD diet demonstrated increase in total cholesterol, triglyceride, low-density lipoprotein cholesterol, alanine aminotransferase and aspartate aminotransferase activities, but decrease in high-density lipoprotein cholesterol. JQLP treatment effectively normalized these parameters in a dose-dependent manner. Furthermore, rats with MCD diet were detected with largely secreted tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6); while JQLP intervention decreased TNF-α and IL-6 secretion, but enhanced IL-4 content. Additionally, miR-27 upregulation and PPARγ downregulation were induced in liver tissues of rats with MCD diet, which were counteracted by JQLP treatment.
JQLP can ameliorate NASH progression, potentially through the regulation of miR-27/ PPARγ axis. JQLP may be a promising therapeutic candidate worthy of further clinical investigation for NASH treatment.

PMID:
42365404
Bibliographic data and abstract were imported from PubMed on 28 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.